사이토카인 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 사이토카인 유형별, 치료 용도별, 지역별, 경쟁별(2020-2030년)

The Global Cytokine Market was valued at USD 95.23 billion in 2024 and is expected to witness significant expansion, reaching new heights by 2030 with a projected CAGR of 7.82%. Cytokines-key signaling proteins involved in immune system regulation, inflammation, and intercellular communication-have become pivotal in both therapeutic innovation and disease management.

Ongoing advancements in cytokine biology are unlocking novel clinical applications across cancer, autoimmune, and infectious diseases. The surge in chronic illness prevalence globally has driven the development and uptake of cytokine-based therapies, positioning the market for sustained growth.

Therapeutic innovations, supported by growing R&D investments and precision medicine initiatives, are transforming cytokine therapies into integral components of modern treatment protocols. Increasing reliance on biologics and personalized healthcare solutions is further fueling product development across biopharmaceutical and biotechnology industries. With expanding clinical use and heightened industry focus, the cytokine market is poised for dynamic evolution in the years ahead.

Key Market Drivers

Strategic Importance of Research and Development (R&D)

R&D remains a fundamental catalyst for growth in the cytokine market. As the biological complexity of cytokines becomes better understood, new opportunities for drug development and therapeutic application continue to emerge.

In 2023, U.S. biopharmaceutical firms invested nearly USD 96 billion in R&D, underlining the industry's commitment to innovation. This focus has led to:

Development of breakthrough cytokine therapies with improved safety and efficacy profiles

Strengthened competitive positioning for companies offering differentiated solutions

Heightened interest from investors and strategic collaborators

Broader clinical use, thereby expanding the market potential

Robust R&D pipelines, along with strategic collaborations between research institutions and industry stakeholders, are expected to further accelerate the development of targeted cytokine therapies.

Key Market Challenges

Safety and Adverse Effects

The therapeutic use of cytokines presents inherent challenges due to their potent biological activity. While effective, cytokines can produce complex and, at times, unpredictable physiological responses.

Major safety-related issues include:

Prolonged clinical trials to establish safe dosing and treatment parameters

Risk of adverse effects that may affect treatment adoption and patient trust

Heightened regulatory oversight, which may delay approvals and increase compliance burdens

To address these concerns, companies are investing in:

Preclinical models and advanced in vitro studies

Comprehensive safety monitoring during clinical trials

Continued research into molecular mechanisms to enhance targeting and minimize side effects

Key Market Trends

Emergence of Personalized Cytokine Therapies

The cytokine therapy landscape is witnessing a notable shift toward personalized medicine. By leveraging biomarkers and genetic profiling, personalized cytokine treatments offer:

Improved therapeutic outcomes through targeted intervention

Reduced adverse effects via patient-specific dosing strategies

Enhanced acceptance of biologics in mainstream treatment regimens

Pharmaceutical developers are increasingly investing in companion diagnostics, biomarker discovery, and niche formulations to align with this trend. These developments are reshaping therapeutic strategies and enabling a patient-centric approach, which is expected to be a significant market differentiator moving forward.

Key Market Players

• GlaxoSmithKline PLC
• Novartis AG
• Amgen Inc
• Pfizer Inc.
• Sanofi SA
• AstraZeneca plc
• Biocon Limited
• Abbvie Inc
• Johnson and Johnson
• UCB S.A

Report Scope:

In this report, the Global Cytokine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cytokine Market, By Cytokine Type:

• Tumour Necrosis Factor-TNF
• Interleukins-Il
• Interferons-IFN
• Epidermal Growth Factor-EGF
• Other

Cytokine Market, By Therapeutics Application:

• Cancer
• Asthma and Airway Inflammation
• Arthritis
• Other

Cytokine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cytokine Market.

Available Customizations:

Global Cytokine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cytokine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cytokine Type (Tumour Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other)
  • 5.2.2. By Therapeutics Application (Cancer, Asthma and Airway Inflammation, Arthritis, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Cytokine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cytokine Type
  • 6.2.2. By Therapeutics Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cytokine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cytokine Type
      • 6.3.1.2.2. By Therapeutics Application
  • 6.3.2. Canada Cytokine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cytokine Type
      • 6.3.2.2.2. By Therapeutics Application
  • 6.3.3. Mexico Cytokine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cytokine Type
      • 6.3.3.2.2. By Therapeutics Application

7. Europe Cytokine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cytokine Type
  • 7.2.2. By Therapeutics Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cytokine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cytokine Type
      • 7.3.1.2.2. By Therapeutics Application
  • 7.3.2. United Kingdom Cytokine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cytokine Type
      • 7.3.2.2.2. By Therapeutics Application
  • 7.3.3. Italy Cytokine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Cytokine Type
      • 7.3.3.2.2. By Therapeutics Application
  • 7.3.4. France Cytokine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cytokine Type
      • 7.3.4.2.2. By Therapeutics Application
  • 7.3.5. Spain Cytokine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cytokine Type
      • 7.3.5.2.2. By Therapeutics Application

8. Asia-Pacific Cytokine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cytokine Type
  • 8.2.2. By Therapeutics Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cytokine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cytokine Type
      • 8.3.1.2.2. By Therapeutics Application
  • 8.3.2. India Cytokine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cytokine Type
      • 8.3.2.2.2. By Therapeutics Application
  • 8.3.3. Japan Cytokine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cytokine Type
      • 8.3.3.2.2. By Therapeutics Application
  • 8.3.4. South Korea Cytokine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cytokine Type
      • 8.3.4.2.2. By Therapeutics Application
  • 8.3.5. Australia Cytokine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cytokine Type
      • 8.3.5.2.2. By Therapeutics Application

9. South America Cytokine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cytokine Type
  • 9.2.2. By Therapeutics Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cytokine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cytokine Type
      • 9.3.1.2.2. By Therapeutics Application
  • 9.3.2. Argentina Cytokine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cytokine Type
      • 9.3.2.2.2. By Therapeutics Application
  • 9.3.3. Colombia Cytokine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cytokine Type
      • 9.3.3.2.2. By Therapeutics Application

10. Middle East and Africa Cytokine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cytokine Type
  • 10.2.2. By Therapeutics Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cytokine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cytokine Type
      • 10.3.1.2.2. By Therapeutics Application
  • 10.3.2. Saudi Arabia Cytokine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cytokine Type
      • 10.3.2.2.2. By Therapeutics Application
  • 10.3.3. UAE Cytokine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cytokine Type
      • 10.3.3.2.2. By Therapeutics Application

11. Market Dynamics

• 11.1. Driver
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Cytokine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. GlaxoSmithkline PLC
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Amgen Inc
• 14.4. Pfizer Inc.
• 14.5. Sanofi SA
• 14.6. AstraZeneca plc
• 14.7. Biocon Limited
• 14.8. Abbvie Inc
• 14.9. Johnson and Johnson
• 14.10. UCB S.A

15. Strategic Recommendations

16. About Us & Disclaimer